# Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease

> **NCT04857606** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 47 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** AMG 609
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04857606
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-24
- **Primary completion:** 2023-07-19
- **Final completion:** 2023-07-19
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04857606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04857606, "Single Ascending Dose of AMG 609 in Participants With Non-alcoholic Fatty Liver Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04857606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*